Dr Luis Pardo Fernandez
- Research Associate (Therapeutic Science Research)
telephone:
01413304476
email:
Luis.Pardo-Fernandez@glasgow.ac.uk
Institute of Infection, Immunity and Inflammation,, College of Medical, Veterinary and Life Sciences, L319 Glasgow Biomedical Research Centre, University of Glasgow, 120 University Place, G12 8TA
https://orcid.org/0000-0002-4355-1369Publications
2026
Pardo Fernandez, L. et al. (2026) Increased mRNA translation delays tumour initiation and exposes a therapeutic vulnerability in lung cancer. Molecular Cancer, 25, 172. (doi: 10.1186/s12943-026-02680-z) (PMID:42163342) (PMCID:PMC13366719)
Chapple, K. J. et al. (2026) An activity-modulated Transport Route Across Myelin (TRAM) for motor-driven organelle transfer in oligodendrocytes. Nature Neuroscience, (doi: 10.1038/s41593-026-02383-0) (PMID:42538476) (Early Online Publication)
2025
Gounis, M. et al. (2025) Metabolic adaptations of micrometastases alter EV production to generate invasive microenvironments. Journal of Cell Biology, 224(8), e202405061. (doi: 10.1083/jcb.202405061) (PMID:40488669) (PMCID:PMC12147664)
2024
Pardo, Luis 
ORCID: https://orcid.org/0000-0002-4355-1369 and Norman, Jim C. ORCID: https://orcid.org/0000-0002-0098-3014
(2024)
Targeting the secretory program of 3q-amplified lung cancers.
Journal of Clinical Investigation, 134(12),
e181798.
(doi: 10.1172/JCI181798)
(PMID:40047887)
(PMCID:PMC11178543)
Articles
Pardo Fernandez, L. et al. (2026) Increased mRNA translation delays tumour initiation and exposes a therapeutic vulnerability in lung cancer. Molecular Cancer, 25, 172. (doi: 10.1186/s12943-026-02680-z) (PMID:42163342) (PMCID:PMC13366719)
Chapple, K. J. et al. (2026) An activity-modulated Transport Route Across Myelin (TRAM) for motor-driven organelle transfer in oligodendrocytes. Nature Neuroscience, (doi: 10.1038/s41593-026-02383-0) (PMID:42538476) (Early Online Publication)
Gounis, M. et al. (2025) Metabolic adaptations of micrometastases alter EV production to generate invasive microenvironments. Journal of Cell Biology, 224(8), e202405061. (doi: 10.1083/jcb.202405061) (PMID:40488669) (PMCID:PMC12147664)
Pardo, Luis ORCID: https://orcid.org/0000-0002-4355-1369 and Norman, Jim C. ORCID: https://orcid.org/0000-0002-0098-3014
(2024)
Targeting the secretory program of 3q-amplified lung cancers.
Journal of Clinical Investigation, 134(12),
e181798.
(doi: 10.1172/JCI181798)
(PMID:40047887)
(PMCID:PMC11178543)
Prior publications
Article
Joseph A. Waldron et al. (2023) eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancers Luis Pardo-Fernandez. (doi: 10.1101/2023.11.10.566546)
Madeleine Moore et al. (2023) The eIF4A2 negative regulator of mRNA translation promotes extracellular matrix deposition to accelerate hepatocellular carcinoma initiation Luis Pardo-Fernandez. (doi: 10.1101/2023.08.16.553544)
Arantxa Golbano, Luis Pardo, Carmen M. Menacho, Marina Rierola, Enrique Claro, Levi B. Wood, Roser Masgrau, Elena Galea (2022) Defective neuritogenesis in Abcd1/2 deficient rat neurons due to intrinsic and astrocyte-dependent mechanisms Crossref. (doi: 10.1101/2022.09.30.510337)
(2017) CREB Regulates Distinct Adaptive Transcriptional Programs in Astrocytes and Neurons Scientific Reports Luis Pardo-Fernandez. ISSN 2045-2322 (doi: 10.1038/s41598-017-06231-x)
(2017) CREB decreases astrocytic excitability by modifying subcellular calcium fluxes via the sigma-1 receptor Cellular and Molecular Life Sciences Luis Pardo-Fernandez. ISSN 1420-9071 (doi: 10.1007/s00018-016-2397-5)
(2016) Targeted activation of CREB in reactive astrocytes is neuroprotective in focal acute cortical injury Glia Luis Pardo-Fernandez. ISSN 0894-1491 (doi: 10.1002/glia.22969)
(2012) ATP and noradrenaline activate CREB in astrocytes via noncanonical Ca2+ and cyclic AMP independent pathways Glia Luis Pardo-Fernandez. ISSN 0894-1491 (doi: 10.1002/glia.22352)
Grants
Grants and Awards listed are those received whilst working with the University of Glasgow.
- Defining aggressive growth signatures in early stage NSCLC to identify biomarkers of disease progression in liquid biopsy
Cancer Research UK
2026 - 2027